Co-Founder and Director
Phoenix Headache Institute
Scottsdale, Arizona, United States
After obtaining his Bachelor of Science degree in neurobiology from Allegheny College, Dr. Eross competed one year of basic science research (investigating the enteric nervous system of the gut) at the University of Pittsburgh Medical Center. Following his research experience, he went on to graduate with a medical degree from Ohio University College of Osteopathic Medicine. He then completed a one-year internship with emphasis in internal medicine at West Penn Hospital followed by neurology residency training at the University of Texas Health Science Center at San Antonio. His expertise in headache medicine began by completing a two-year headache-medicine fellowship at Mayo Clinic. Subsequently he joined faculty at Mayo Clinic serving as an Associate Neurology Consultant and Clinical Instructor at the Mayo College of Medicine. While at Mayo Clinic, Dr. Eross was an active reviewer for the scientific journals Headache and Cephalalgia and served as a Clinical Science Contributing Editor to the journal Headache Currents. Dr. Eross went on to become Co-Founder and current Director of the Phoenix Headache Institute in Scottsdale, AZ. He is also currently an Assistant Clinical Professor at Midwestern University, Arizona College of Osteopathic Medicine and clinical faculty in the family practice residency program at Honor Healthcare. In addition to patient care, he remains active in research and education having served as a lead investigator in over sixty headache-related clinical trials and lecturing extensively throughout the United States. His true passion is teaching others “the joy” of successful headache diagnosis and management through a common-sense approach to universal conundrums faced by the busy practitioner. Known by his colleagues as an innovator, his “out-of-the-box” thinking led to the discovery of the natural product GLIACIN® which is now used worldwide for migraine prophylaxis and recognized as the most consistent alternative to indomethacin for individuals with indomethacin-responsive headache syndromes.
Industry Symposium: Clinical Conversations: Exploring the Latest Data from Pfizer *
Thursday, December 4, 2025
12:00 PM - 1:00 PM MST